Lymphoma survivors have an increased long-term risk of chronic kidney disease

References

• Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006;17(12):1749–1760.
   PubMed Web of Science ®Google Scholar
• Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004;22(15):3139–3148.
   PubMed Web of Science ®Google Scholar
• Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2005;23(30):7555–7564.
   PubMed Web of Science ®Google Scholar
• Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005;23(30):7614–7620.
   PubMed Web of Science ®Google Scholar
• Lynce F, Pehlivanova M, Catlett J, et al. Obesity in adult lymphoma survivors. Leuk Lymphoma. 2012;53(4):569–574.
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer. 2007;110(6):1376–1384.
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Spano J-P, Janus N, et al. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol. 2009;70(2):124–133.
   PubMed Web of Science ®Google Scholar
• Yang Y, et al. Renal function and all-cause mortality risk among cancer patients. Medicine (Baltimore). 2016;95(20):e3728.
   PubMed Web of Science ®Google Scholar
• Iff S, Craig JC, Turner R, et al. Reduced estimated GFR and cancer mortality. Am J Kidney Dis. 2014;63(1):23–30.
   PubMed Web of Science ®Google Scholar
• Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33(4):278–285.
   PubMed Web of Science ®Google Scholar
• Ubukata M, Hara M, Nishizawa Y, et al. Prevalence and mortality of chronic kidney disease in lymphoma patients: a large retrospective cohort study. Medicine (Baltimore). 2018;97(2):e9615.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.
   PubMed Web of Science ®Google Scholar
• Sato KK, Hayashi T, Harita N, et al. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care. 2009;32(4):644–646.
   PubMed Web of Science ®Google Scholar
• Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–29.
   PubMed Web of Science ®Google Scholar
• Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2018 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2019;73(3 Suppl. 1):A7–A8.
   PubMed Web of Science ®Google Scholar
• Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–2047.
   PubMed Web of Science ®Google Scholar
• Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950;29(5):496–507.
   PubMed Web of Science ®Google Scholar
• Yu M-A, Sánchez-Lozada LG, Johnson RJ, et al. Oxidative stress with an activation of the renin–angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28(6):1234–1242.
   PubMed Web of Science ®Google Scholar
• Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122.
   PubMed Web of Science ®Google Scholar
• Sturm G, Kollerits B, Neyer U, et al. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2008;43(4):347–352.
   PubMed Web of Science ®Google Scholar
• Kanji T, Gandhi M, Clase CM, et al. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16:58.
   PubMed Web of Science ®Google Scholar
• Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;66(6):945–950.
   PubMed Web of Science ®Google Scholar
• Gargiulo R, Suhail F, Lerma EV. Hypertension and chronic kidney disease. Dis Mon. 2015;61(9):387–395.
   PubMed Web of Science ®Google Scholar
• Zoungas S, Woodward M, Li Q, et al. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia. 2014;57(12):2465–2474.
   PubMed Web of Science ®Google Scholar
• Davis TM, Stratton IM, Fox CJ, et al. U.K. Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM. Diabetes Care. 1997;20(9):1435–1441.
   PubMed Web of Science ®Google Scholar
• Vejakama P, Thakkinstian A, Lertrattananon D, et al. Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012;55(3):566–578.
   PubMed Web of Science ®Google Scholar